Knowledge Distillery

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a…

COVID-19 dynamics after a national immunization program in Israel

COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

In this phase 1, double-blind, placebo-controlled, block-randomised trial the authors aimed to assess the safety and immunogenicity of an…

CoV2 preS dTM is a stabilised pre-fusion spike protein vaccine produced in a baculovirus expression system being developed against SARS-CoV-2. In this…

In this article the authors examined vaccine effectiveness among health care workers at the Hadassah Hebrew University Medical Center (HHUMC), a…

Since the start of the vaccination campaign, the development of COVID-19 has been reported in persons who have received one or both doses of mRNA-1273…

Authors describe mRNA1273-elicited binding and neutralizing antibodies in 33 healthy adults in an ongoing phase 1 trial, 180 days after the second…

Whether or not people who have been infected SARS-CoV-2 should be vaccinated is unclear. This observational cohort study, the authors enrolled 100…

In this article, the authors report findings in five patients who presented with venous thrombosis and thrombocytopenia 7 to 10 days after receiving…

In this article, the authors report findings in 23 patients who presented with thrombosis and thrombocytopenia 6 to 24 days after receiving the first…